EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) exon 20 insertions constitute a significant subset of EGFR mutations in lung adenocarcinoma, posing therapeutic challenges.
• Current EGFR inhibitors show limited efficacy against these specific mutations, leaving a critical unmet need in precision oncology.

Purpose of the Study:

• To evaluate the efficacy of various EGFR inhibitors against EGFR exon 20 insertion mutants using preclinical models.
• To explore novel therapeutic strategies targeting the vulnerabilities of EGFR exon 20 insertion mutations.

Main Methods:

• Development and utilization of preclinical models representing common EGFR exon 20 insertion mutations.
• Assessment of first-, second-, and third-generation EGFR inhibitors' activity.
• Investigation of the association between EGFR exon 20 insertion mutants and the Hsp90 chaperone system.
• Evaluation of the Hsp90 inhibitor luminespib (AUY922) on EGFR exon 20 insertion mutants and downstream signaling.
• Clinical case study of a patient with EGFR exon 20 insertion-positive lung adenocarcinoma treated with luminespib.

Main Results:

• Standard EGFR inhibitors were ineffective against EGFR exon 20 insertion mutants at concentrations sparing wild-type EGFR.
• EGFR exon 20 insertion mutants were found to be dependent on the Hsp90 chaperone system.
• The Hsp90 inhibitor luminespib demonstrated degradation of EGFR exon 20 mutations, downstream targets, and induced apoptosis in preclinical models.
• A patient with EGFR inhibitor-insensitive lung adenocarcinoma harboring an exon 20 insertion mutation showed a radiographic response to luminespib.

Conclusions:

• EGFR exon 20 insertion mutations exhibit a dependency on Hsp90, representing a druggable vulnerability.
• Luminespib, an Hsp90 inhibitor, shows promise in targeting these previously treatment-resistant mutations.
• This finding supports the ongoing clinical investigation of luminespib for lung adenocarcinomas with EGFR exon 20 insertions, addressing a significant unmet need.